Key Highlights
- Resonance Health requested a trading halt from the start of trading on 23 October 2026.
- The company expects to make a market-sensitive announcement on preliminary results of its Liver Fibrosis Extended-Proof-of-Concept clinical trial.
- The same announcement is expected to cover a placement to sophisticated and/or institutional investors.
- The halt runs until the earlier of the announcement or the start of normal trading on Tuesday 27 October 2026.
Resonance Health Limited (ASX:RHT) is in a trading halt following a request lodged with ASX on 22 October 2026. ASX Supervision published its market announcement on 23 October 2026, confirming that trading in RHT securities would be halted at the company's request, pending the release of an announcement. The company's letter says the halt is needed to manage its continuous disclosure obligations.
What the Company Expects to Announce
In its letter to ASX, Resonance Health said it expects to make a market-sensitive announcement in relation to two matters. The first is the preliminary results of its Liver Fibrosis Extended-Proof-of-Concept clinical trial. The second is a placement to sophisticated and/or institutional investors. Neither the trial results nor the terms of the placement, such as its size or price, were included in the documents released.
The company asked for the halt to begin from the commencement of trading on 23 October 2026, and to last until the earlier of the start of normal trading on Tuesday 27 October 2026 or the release of the announcement.
How the Halt Works
Under ASX Listing Rule 17.1, a company can ask for a halt when it needs time to manage its disclosure obligations. During the halt, RHT securities cannot be traded on the ASX market. ASX said that unless it decides otherwise, the securities will stay halted until the earlier of the start of normal trading on 27 October 2026 or the release of the announcement.
Resonance Health said it is not aware of any reason why the halt should not be granted, or of any other information necessary to inform the market about it. The request was signed by the company's Non-executive Director and Company Secretary.
Why This Could Matter
The company has described the announcement as market sensitive and expects to cover both the trial results and the placement in it. Until the announcement is released, the content of the preliminary results, including whether they meet the trial's objectives, is not known. The planned placement would also add to the company's share capital if it proceeds, although no figures have been disclosed.
Where Things Stand
RHT securities remain halted, and the market is waiting on a single announcement covering the Liver Fibrosis trial results and the placement. If it is not released earlier, trading is due to resume at the start of trading on Tuesday 27 October 2026.






Please wait processing your request...